Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$1.12
-$0.03(-3.70%)
At close: 4:00 PM EST
$1.12
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.77 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)1.49M
Market Cap
$102.47M
Enterprise Value$90.33
Total Cash (Recent Filing)$5.49M
Total Debt (Recent Filing)$508.00K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding119,354,065
10 Day Avg. Volume2,232,036
30 Day Avg. Volume1,491,518
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Momentum (Fast Track)Fast Track designation and prior FDA alignment on registrational pathways provide durable regulatory engagement and a clearer path to accelerated approval. This can shorten timelines, increase agency interaction, and materially de-risk late-stage development and partner interest over the next 2–6 months and beyond.
Manufacturing & IP ProtectionA newly issued manufacturing patent through 2044 (and potential method-of-use to 2046) strengthens Oncolytics’ commercialization moat by protecting scale-up processes. Durable IP lowers competitor risk, supports manufacturability, and improves partner/licensing leverage for future commercialization discussions.
Strong Clinical Efficacy & Mechanism DataRobust REO 022 results and translational ASCO data demonstrate durable responses and immune-priming mechanism across GI tumors. Such differentiated clinical efficacy and mechanistic rationale improve the chance of successful registrational study designs and make the asset more attractive for partnerships or accelerated approval strategies.
Bears Say
No Product RevenueAs a clinical-stage company with zero reported product revenue, Oncolytics must rely on external financing, collaborations, or milestone payments to fund operations. Lack of recurring commercial cash flow increases dependency on capital markets and heightens dilution risk absent a near-term approval or partnership.
Negative Equity & Shrinking AssetsEquity turning negative and a marked decline in total assets materially weaken the financial cushion. Even with low absolute debt, deteriorating balance-sheet metrics reduce solvency buffers, constrain strategic optionality, and increase the likelihood of dilutive financing or dilutive partnerships.
Persistent Cash BurnSustained negative operating and free cash flow (~-$20.9M TTM) means the company will need additional capital to complete registrational programs. Continued burn pressures runway, can force accelerated or unfavorable deal terms, and elevates execution risk if financing windows tighten.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.77 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $102.47M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Jul 31, 2026 which is in 8 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on May 14, 2026. The company reported -$0.078 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.036.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.05.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 119,354,065 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.078 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.523%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (435.71% Upside)
$6.00 (435.71% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.89%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―